Kling Douglas F's Form 4 filing
NewAmsterdam Pharma Co N.V. (NAMS) · filed Jun 18, 2025
- Accession no.
- 0000950170-25-087937
- Filed
- Jun 18, 2025
- Trade date
- Jun 16, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.93M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kling Douglas FCIK 0001699022 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Ordinary Shares | MOption exerciseAcquired | +78,101 | $10.00 | +$781,010 | 122,101 | Direct | |
| Jun 16, 2025 | Ordinary Shares | MOption exerciseAcquired | +21,899 | $10.90 | +$238,699.1 | 144,000 | Direct | |
| Jun 16, 2025 | Ordinary Shares | SSaleDisposed | −81,891 | $19.19 | −$1,571,488.29 | 62,109 | Direct | |
| Jun 16, 2025 | Ordinary Shares | SSaleDisposed | −18,109 | $19.75 | −$357,652.75 | 44,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Ordinary Shares | MOption exerciseDisposed | −78,101 | $0.00 | $0 | 372,829 | Direct | |
| Jun 16, 2025 | Ordinary Shares | MOption exerciseDisposed | −21,899 | $0.00 | $0 | 261,314 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.